Related Experiment Video
Updated: May 5, 2026

Quantification of the Potential Impact of Glyphosate-Based Products on Microbiomes
Published on: January 10, 2022
Evergreening by whom? A review of secondary patents for omeprazole
1Griffith Hack, 161 Collins Street, Melbourne, Victoria 3000, Australia. mike.lloyd@griffithhack.com.au.
Abstract:
Evergreening, or the practice of technology developers to retain legal protection over valuable drugs beyond the normal patent term, is a well known practice by originators of successful drugs. Generic competitors also attempt similar strategies for commercial reasons. In this paper we look at secondary US and European patents in relation to the 'blockbuster' drug omeprazole (e.g., Prilosec® by AstraZeneca among other brands), with these secondary patents selected because they refer to the 'omeprazole' in either the title, abstract, Derwent Title or first claim. We find that 485 patents meet this criteria, with only 29% owned by the drugs originator (or known subsidiaries or predecessors). AstraZeneca was also the leading applicant by a number of measures, including grant ratio, number of patents filed, forward citation count, family member count and claim breadth.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
FDA Approved Drugs: Changes to Approved Drugs
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

